IMDX logo

INSIGHT MOLECULAR DIAGNOSTIC

IMDXNASDAQ
🏆 #4081 by market capUS Equity
$3.38▲ $0.22 (+6.47%)
After hours · at close
🔔
Track IMDX
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 6.5%
7d▼ 18.1%
14d▼ 16.3%
30d▼ 18.9%
ytd▼ 55.1%
1y▲ 3.8%
🏦Market Cap
$109M
Small Cap
📈Revenue Growth (YoY)
+115.6%
High Growth
📊Gross Margin
11.2%
Thin
💵FCF Margin
-1848.8%
Thin
⚖️P/S Ratio
61.5x
Expensive
Otter Score
60
Fair

Trading Snapshot

Day Range
$3.35 – $3.40
52-Week Range
$2.42 – $8.51
Volume
$2.42B
Avg Volume
$2.62B
Shares Outstanding
32.3M
Next Earnings
Dec 3, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$239,000
P/E Ratio
-2.1
P/S Ratio
61.5x
EPS (TTM)
$-1.34
Dividend Yield
0.00%
Dilution (1yr)
+75.3%

Why Investors Own IMDX

  • ✓High-growth profile — revenue up +29.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 40% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

IMDX logo

INSIGHT MOLECULAR DIAGNOSTIC

IMDX
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4M▲ +115.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
4.7%▼ −88.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$31M▼ −49.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$25M▲ +19.5% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
30.5M▲ +75.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$8M▲ +$3M YoY
StockOtter · stockotter.space

About INSIGHT MOLECULAR DIAGNOSTIC

OncoCyte Corporation functions as a molecular diagnostics firm specializing in the research, development, and market introduction of distinctive, laboratory-developed tests aimed at cancer identification. Its operations span both the United States and international territories. The company's key offerings include DetermaRx, a molecular diagnostic tool tailored for detecting early-stage adenocarcinoma of the lung, and DetermaIO, a proprietary gene expression analysis. Additionally, OncoCyte provides a range of expert services, such as biomarker discovery, assay design and refinement, and clinical trial assistance, which encompass offering various biomarker tests to pharmaceutical partners. A strategic partnership with Life Technologies Corporation focuses on the collaborative development and commercialization of the Oncomine Comprehensive Assay Plus and Determa IO assay, intended for integration with the Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was founded in 2009 and maintains its principal office in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$4.37
▲ +29.5% Upside
High Target$5.36
Low Target$3.56
Based on 41 analysts

Latest News & Updates

🚀
Barron’s·2h ago

INSIGHT MOLECULAR DIAGNOSTIC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift IMDX price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

INSIGHT MOLECULAR DIAGNOSTIC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.